Efficacy_and_safety_considerations_in_women_with_uterine_leiomyomas_treated_with_gonadotropin-releasing_hormone_agonists:_the_estrogen_threshold_hypothesis._Gonadotropin-releasing_hormone_agonists_induce_a_reversible_hypogonadotropic_hypogonadal_environment._Leiomyomas_are_common,_estrogen-sensitive,_benign_neoplasms_that_decrease_in_size_by_40%_to_50%_during_gonadotropin-releasing_hormone_agonist_treatment._During_gonadotropin-releasing_hormone_agonist_therapy_most_women_are_amenorrheic._After_discontinuation_of_gonadotropin-releasing_hormone_agonist_treatment,_uterine_and_myoma_size_increase_and_a_return_to_pretreatment_menstrual_patterns_often_occurs._Concerns_about_the_safety_of_long-term_hypoestrogenism_have_made_long-term_gonadotropin-releasing_hormone_agonist_administration_an_undesirable_treatment_strategy._This_article_focuses_on_the_use_of_gonadotropin-releasing_hormone_agonists_as_preoperative_therapy_in_selected_women_undergoing_hysterectomy_or_myomectomy_and_the_combination_of_a_gonadotropin-releasing_hormone_agonist_with_estrogen-progestin_"add-back"_treatment_as_a_potential_long-term_medical_therapy_for_women_with_symptomatic_leiomyomas._Finally,_an_estrogen_threshold_hypothesis_to_assess_the_effects_of_circulating_estrogen_concentrations_on_different_tissues,_is_presented.